These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 18477735)

  • 1. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 3. A critical analysis of studies of state drug reimbursement policies: research in need of discipline.
    Soumerai SB; Ross-Degnan D; Fortess EE; Abelson J
    Milbank Q; 1993; 71(2):217-52. PubMed ID: 8510601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.
    Lingaratnam SM; Kirsa SW; Mellor JD; Jackson J; Crellin W; Fitzsimons M; Zalcberg JR
    Aust Health Rev; 2011 May; 35(2):204-10. PubMed ID: 21612735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare and drug pricing.
    Iglehart JK
    N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
    [No Abstract]   [Full Text] [Related]  

  • 8. Financial barriers to implementing combination vaccines: perspectives from pediatricians and policy makers.
    Gidengil CA; Rusinak D; Allred NJ; Luff D; Lee GM; Lieu TA
    Clin Pediatr (Phila); 2009 Jun; 48(5):539-47. PubMed ID: 19318705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waiting for reimbursement of new medicines in Canada: it's time for a rethink.
    Skinner BJ
    Pharmacoeconomics; 2008; 26(8):629-32. PubMed ID: 18620457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database.
    van Driel ML; Vander Stichele R; Elseviers M; De Sutter A; De Maeseneer J; Christiaens T
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1113-22. PubMed ID: 18823069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Politicians', bureaucrats' drug plans deemed too costly for public formularies.
    Kondro W
    CMAJ; 2007 Mar; 176(6):755. PubMed ID: 17353524
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of reimbursement applications for new drugs].
    Aaserud M; Trommald M; Oxman AD; Innvaer S
    Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2619-23. PubMed ID: 12523192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When success sours: PBMs under scrutiny.
    Carroll J
    Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
    [No Abstract]   [Full Text] [Related]  

  • 16. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
    Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
    Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimbursement-Based Economics--What Is It and How Can We Use It to Inform Drug Policy Reform?
    Coyle D; Lee KM; Mamdani M; Sabarre KA; Tingley K
    Headache; 2015; 55 Suppl 4():236-47. PubMed ID: 26178290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.